Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Identifying and Characterizing Autoantibodies in Chronic Lung Rejection

FY 2022-23

Summary
Lung transplantation (LTx) is the only life-saving treatment for patients in the end stages of lung disease. However, long-term survival is poor due to chronic lung rejection. A recent shift in attention to the role of two autoantibodies, proteins that circulate blood and target self-proteins, correlated with chronic rejection has occurred. However, other autoantibodies specific to lung tissue have been seldom examined and whether they have a pathogenetic relationship to donor lung damage is unclear. We hypothesize that autoantibodies circulating via blood precede and mediate donor lung injury that contributes to the development of chronic lung rejection. Novel autoantibodies specifically against lung tissue in LTx patient blood-derived samples will be assessed by protein microarrays enriched for lung proteins. This technique allows the screening of blood-derived samples for many lung targeted autoantibodies at once. Autoantibodies significantly higher in patients that develop chronic rejection will be evaluated for their predictive capacity in chronic rejection-free survival using multivariate survival analyses. Then, structural changes in lung tissue samples, the localization autoantibodies throughout the lung, and fragmented proteins targeted by the autoantibodies in airway fluid samples will be assessed based on patient-specific differences in their levels of circulating autoantibodies. Overall, autoantibodies found to be significant contributors to donor lung damage can guide novel treatment protocols and therapeutics to mitigate this limiting pathology in long-term LTx survival.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486054
Name
Vosoughi Daniel
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying and Characterizing Autoantibodies in Chronic Lung Rejection
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antigen Microarray; Autoantibodies; Chronic Lung Allograft Dysfunction; Lung Transplant; Rejection; Tropoelastin
Abstract
Lung transplantation (LTx) is the only life-saving treatment for patients in the end stages of lung disease. However, long-term survival is poor due to chronic lung rejection. A recent shift in attention to the role of two autoantibodies, proteins that circulate blood and target self-proteins, correlated with chronic rejection has occurred. However, other autoantibodies specific to lung tissue have been seldom examined and whether they have a pathogenetic relationship to donor lung damage is unclear. We hypothesize that autoantibodies circulating via blood precede and mediate donor lung injury that contributes to the development of chronic lung rejection. Novel autoantibodies specifically against lung tissue in LTx patient blood-derived samples will be assessed by protein microarrays enriched for lung proteins. This technique allows the screening of blood-derived samples for many lung targeted autoantibodies at once. Autoantibodies significantly higher in patients that develop chronic rejection will be evaluated for their predictive capacity in chronic rejection-free survival using multivariate survival analyses. Then, structural changes in lung tissue samples, the localization autoantibodies throughout the lung, and fragmented proteins targeted by the autoantibodies in airway fluid samples will be assessed based on patient-specific differences in their levels of circulating autoantibodies. Overall, autoantibodies found to be significant contributors to donor lung damage can guide novel treatment protocols and therapeutics to mitigate this limiting pathology in long-term LTx survival.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vosoughi, Daniel
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~